[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"article-8927b26e-233f-4624-9ba7-072a6e8f7823--":3,"related-articles-undefined-undefined-02d1d84c-aa47-4fbe-b427-acae28018aa8-true":25},{"id":4,"type":5,"title":6,"subtitle":7,"pubDate":8,"logoUrl":9,"anpFeedCategory":10,"organisationTitle":11,"thirdParty":12,"body":13,"imageUrls":14,"city":16,"website":17,"orgId":18,"branches":19,"description":23,"quoteReason":24},"8927b26e-233f-4624-9ba7-072a6e8f7823","PRESSRELEASE","VectorY Therapeutics Raises €74.5 Million to Advance Neurodegenerative Disease Pipeline","New antibody technology offers hope for future treatments of ALS and Huntington’s disease.","2026-11-11T14:00:00.031+01:00","https:\u002F\u002Fwww.persberichten.nl\u002Ffile\u002Flogos\u002F02d1d84c-aa47-4fbe-b427-acae28018aa8\u002F1b1ef8b4-22a4-4ea9-953d-bd357be25a24.jpg","Economie","Vigo Consulting",false,"\u003Cp>\u003Cimg src=\"https:\u002F\u002Forder.perssupport.nl\u002Ffile\u002Fpressrelease\u002F02d1d84c-aa47-4fbe-b427-acae28018aa8\u002F8927b26e-233f-4624-9ba7-072a6e8f7823\u002FVectoryLABHennis202513.jpg\" \u002F>\u003C\u002Fp>\n\u003Cp>\u003C\u002Fp>\n\u003Cul>\n \u003Cli>\u003Cem>New investors include Angelini Ventures, Invest-NL and the European Investment Bank (EIB); returning investors include Forbion (Growth and Ventures strategies), EQT Life Sciences, MRL Ventures, Insight Partners, BioGeneration Ventures (BGV), Eli Lilly and Company, and the ALS Investment Fund\u003C\u002Fem>\u003C\u002Fli>\n\u003C\u002Ful>\n\u003Cp>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>Amsterdam, the Netherlands, and Boston, MA – November 11, 2026\u003C\u002Fstrong> - VectorY Therapeutics (“VectorY”), a clinical-stage biotechnology company pioneering vectorized antibody therapies for neurodegenerative diseases, today announced €74.5 million ($83.5 million) in new financing to advance its clinical and preclinical pipeline. The financing includes new investors Angelini Ventures, Invest-NL and the EIB, alongside returning investors Forbion, through its Growth and Ventures strategies, EQT Life Sciences, MRL Ventures, Insight Partners, BGV, Eli Lilly and Company, and the ALS Investment Fund. The substantial participation of existing and new investors underscores confidence in VectorY’s platform, pipeline and potential to create long-term value.\u003C\u002Fp>\n\u003Cp>\u003C\u002Fp>\n\u003Cp>Proceeds will support the advancement of VectorY’s lead program, VTx-002, through key clinical milestones, including the final readout of the PIONEER-ALS® Phase 1\u002F2 clinical study. The global study is evaluating VTx-002 in people living with amyotrophic lateral sclerosis (ALS). In September 2026, VectorY announced the expansion of PIONEER-ALS from 12 to 36 participants, broadening the study’s evaluation of the investigational therapy. The financing will also support VectorY’s broader pipeline, including VTx-003 for Huntington’s disease and additional programs targeting neurodegenerative diseases.\u003C\u002Fp>\n\u003Cp>\u003C\u002Fp>\n\u003Cp>“Neurodegenerative diseases represent some of the most complex challenges in medicine, and patients and families urgently need new treatment options. This financing reflects strong confidence in our team, our platform and the potential of our pipeline,”\u003Cstrong> said Jim Scibetta, chief executive officer, VectorY\u003C\u002Fstrong>. “It will support the advancement of VTx-002 through important clinical milestones, including the final readout of PIONEER-ALS, while enabling us to leverage our vectorized antibody platform to expand its application in multiple neurodegenerative diseases across our pipeline. We are grateful for the continued support of our existing investors and welcome our new partners as we work to advance care for patients.” \u003C\u002Fp>\n\u003Cp>\u003C\u002Fp>\n\u003Cp>“We believe VectorY is building a compelling approach to one of the most challenging areas of medicine. Its progress with VTx-002, including the expansion of the PIONEER-ALS study, is an important step in evaluating the program’s potential. This financing will help the company advance that work while developing additional programs, including VTx-003 for Huntington’s disease. We are pleased to continue supporting VectorY as it translates its platform into potential pioneering treatment options for people living with neurodegenerative diseases,” \u003Cstrong>said Wouter Joustra, General Partner at Forbion.\u003C\u002Fstrong>\u003C\u002Fp>",[15,15],"https:\u002F\u002Flh3.googleusercontent.com\u002F_C1yT3iwg5Y6WIh2ay1kz7ygO1OPQtRSKAsvcbO-BPLxvPg_7zt85MFjrpPEx_eynSBU197ejLLzRMf-u8DS98cZc8rNGsR4","Amsterdam","https:\u002F\u002Fwww.vectorytx.com\u002F","02d1d84c-aa47-4fbe-b427-acae28018aa8",[20],{"id":21,"title":22},"26100","Economie en geld","New investors include Angelini Ventures, Invest-NL and the European Investment Bank (EIB); returning investors include Forbion (Growth and Ventures strategies),","",[26,30,41,51,60,70,79,89,97,108],{"id":4,"title":6,"subtitle":7,"pubDate":8,"logoUrl":9,"thirdParty":12,"imageUrls":27,"orgId":18,"branches":28,"description":23},[15,15],[29],{"id":21,"title":22},{"id":31,"title":32,"subtitle":24,"pubDate":33,"logoUrl":34,"thirdParty":12,"imageUrls":35,"orgId":18,"branches":38,"description":40},"343931a6-55d4-4974-a1cf-470b44316e55","VÆRIDION haalt ruim € 124 miljoen op voor opschaling elektrisch vliegen","2026-11-05T09:00:00.034+01:00","https:\u002F\u002Fwww.persberichten.nl\u002Ffile\u002Flogos\u002F02d1d84c-aa47-4fbe-b427-acae28018aa8\u002F93247b19-443d-461c-b088-0ed33a234861.jpg",[36,37,36,37],"https:\u002F\u002Flh3.googleusercontent.com\u002Fq-jW2GWLgn7p4aem6Y9Vm5Mx8-hPVveIA1GyYlWixdlkLgF7DMEw8SDehWJlvMpBEpxppVg-o5HyrIfOZI9H3Cp2_dQW8Y_KUg","https:\u002F\u002Flh3.googleusercontent.com\u002FYV1_Mw_kbzz9pLJjKSJfH15te5r_vLsvUjMb4ot76lW-A30nadiFg8phR2buta-tyAqb3oc4rz24V3ANssgsvILDJXFmqXu6fg",[39],{"id":21,"title":22},"München, 3 november 2026 – VÆRIDION heeft een investeringsronde van € 30 miljoen afgerond. De ronde wordt geleid door SHIFT Invest en Invest-NL en is bedoeld vo",{"id":42,"title":43,"pubDate":44,"logoUrl":45,"thirdParty":12,"imageUrls":46,"orgId":18,"branches":48,"description":50},"d7a2b398-12ab-40d6-bc50-383642094ea4","Invest-NL en Bpifrance breiden samenwerking uit voor Europese technologiekampioenen","2026-10-16T08:29:20.225+02:00","https:\u002F\u002Fwww.persberichten.nl\u002Ffile\u002Flogos\u002F02d1d84c-aa47-4fbe-b427-acae28018aa8\u002F11a05ee8-05b3-4a36-a7ac-2ac4b0e7ed2f.jpg",[47,47],"https:\u002F\u002Flh3.googleusercontent.com\u002FCuXXUf81N-YkoULy0tURl4VbfVazlRw-axSzqczzI8OjbJT_7uenn-P24BR7jz4VzQ1uzHKI-D_VOjswGRbs-DHDve9y2xHZ",[49],{"id":21,"title":22},"Invest-NL en de Franse publieke investeringsinstelling Bpifrance gaan nauwer samenwerken om Europese technologiebedrijven te financieren en in Europa te laten d",{"id":52,"title":53,"pubDate":54,"logoUrl":45,"thirdParty":12,"orgId":18,"branches":55,"description":59},"0f8c70a2-01fc-4be4-b749-62de8c3a0861","'Koppel aanbetaling aan zekerheid over netcapaciteit'","2026-10-14T12:48:32.790+02:00",[56],{"id":57,"title":58},"27100","Energie en brandstoffen","Verduurzaming wordt afgeremd door de hoge kosten voor een netaansluiting vooraf. Bedrijven die willen overstappen op schone stroom moeten jaren voordat er stroo",{"id":61,"title":62,"pubDate":63,"logoUrl":64,"thirdParty":12,"imageUrls":65,"orgId":18,"branches":67,"description":69},"be010a59-f7b4-4f48-9fde-5a7a9dfbdbc8","Morphotonics closes €40M+ Series B to solve AI-glasses’ hidden manufacturing bottleneck","2026-09-22T16:30:57.213+02:00","https:\u002F\u002Fwww.persberichten.nl\u002Ffile\u002Flogos\u002F02d1d84c-aa47-4fbe-b427-acae28018aa8\u002F287836a8-6ad0-4365-aec9-9c348181c458.jpg",[66,66],"https:\u002F\u002Flh3.googleusercontent.com\u002FaUFwo4TUmKWG5RnA3jA3StBJAXCt5cJZalFVqstk6MpDC9io5t9a3YGkOVeTMKpdYxrRUX_yuV4Y1sFq8PgIi3eauelMCZKGnQ",[68],{"id":21,"title":22},"Global deeptech player Morphotonics has closed a Series B financing round of more than €40 million to scale its manufacturing technology for AI glasses, Augment",{"id":71,"title":72,"pubDate":73,"logoUrl":45,"thirdParty":12,"imageUrls":74,"orgId":18,"branches":76,"description":78},"9aa18e4d-8fdf-4e25-953d-1577ff9377ba","Nederland kan biotechpositie versterken door verbinding met hightechsector","2026-09-18T08:00:00.032+02:00",[75],"https:\u002F\u002Forder.perssupport.nl\u002Ffile\u002Fpressrelease\u002F02d1d84c-aa47-4fbe-b427-acae28018aa8\u002F9aa18e4d-8fdf-4e25-953d-1577ff9377ba\u002FDeepDiveEnablingBiotechInvestNL.pdf",[77],{"id":21,"title":22},"Nederland heeft sterke biotechkennis én een internationaal toonaangevende hightechsector, maar benut de combinatie nog te weinig. Een nieuwe analyse van Invest-",{"id":80,"title":81,"pubDate":82,"logoUrl":45,"thirdParty":12,"imageUrls":83,"orgId":18,"branches":86,"description":88},"71ca2441-cf97-41cb-abd8-addc9c88ca4e","Realistische aannames maken FOAK-projecten beter financierbaar","2026-09-08T08:30:00.055+02:00",[84,84,85],"https:\u002F\u002Flh3.googleusercontent.com\u002FLw5onko3MeKX4agPPX98PuQpMH1fN3htH4wLFi6OH44KgKuh9JSI_WmFvRZcbgu5zQh6GZhnFQJ6HRCDkHxSiLB3ABW5FCRqwx0","https:\u002F\u002Forder.perssupport.nl\u002Ffile\u002Fpressrelease\u002F02d1d84c-aa47-4fbe-b427-acae28018aa8\u002F71ca2441-cf97-41cb-abd8-addc9c88ca4e\u002FEMBARGOEDInvestNLFirstofaKindstudybyAFRY.pdf",[87],{"id":21,"title":22},"De stap van bewezen technologie naar de eerste commerciële fabriek is voor veel innovatieve bedrijven een belangrijk financieringsknelpunt. Invest-NL publiceert",{"id":90,"title":91,"pubDate":92,"logoUrl":93,"thirdParty":12,"orgId":18,"branches":94,"description":96},"d056eabf-4e8b-448d-be6e-83f1fee420fc","VitalFluid haalt €17,2 miljoen op voor internationale uitrol van duurzame gewasbescherming","2026-08-25T08:30:00.043+02:00","https:\u002F\u002Fwww.persberichten.nl\u002Ffile\u002Flogos\u002F02d1d84c-aa47-4fbe-b427-acae28018aa8\u002F2b7dac6a-c04a-4cdf-b431-a8550a05653d.jpg",[95],{"id":21,"title":22},"EINDHOVEN, 25 augustus 2026 – VitalFluid, ontwikkelaar van innovatieve plasmatechnologie voor duurzame gewasbescherming, kondigt vandaag de succesvolle afrondin",{"id":98,"title":99,"pubDate":100,"logoUrl":101,"thirdParty":12,"imageUrls":102,"orgId":18,"branches":105,"description":107},"2ea871d5-5d64-4606-9ce9-0f5e7667c219","Xeltis raises €20.5m to advance aXess™ toward FDA approval and US launch","2026-07-28T09:30:00.035+02:00","https:\u002F\u002Fwww.persberichten.nl\u002Ffile\u002Flogos\u002F02d1d84c-aa47-4fbe-b427-acae28018aa8\u002Fcc3db47a-d423-425f-b22c-49be9f09b001.jpg",[103,104,103,104],"https:\u002F\u002Flh3.googleusercontent.com\u002FyQA_0WAjQxLQXlQLXb3fAMfsYPDYw5N95K3yI635n0PDoxiZrnb1PZe2VlOdP0bK6z1Pxncwq8qrrcL2ByX62OeYPArSoTedrQ","https:\u002F\u002Flh3.googleusercontent.com\u002FwUjLBpJ2i4lJs1Yg0ZyqoF24maNyD4R8ugHOBElUYykc1-R2i-BmL7ERosPl15KWvgHkF2Z38wnX90VTr0xsNRrH15ZRnJLSU1M",[106],{"id":21,"title":22},"New investor Horizon 3 Healthcare led the round, which was supported by the European Innovation Council, Invest-NL, VI Partners, EQT Life Sciences, DaVita and o",{"id":109,"title":110,"pubDate":111,"logoUrl":112,"thirdParty":12,"imageUrls":113,"orgId":18,"branches":115,"description":117},"057ed31b-02ed-4234-bc5e-88697322b697","Keiron haalt €20,7 miljoen op voor revolutionaire LiFT-soldeerpastaprints","2026-07-21T08:30:38.773+02:00","https:\u002F\u002Fwww.persberichten.nl\u002Ffile\u002Flogos\u002F02d1d84c-aa47-4fbe-b427-acae28018aa8\u002F7ca3bd4d-89ba-48fc-aec9-24da897e0e6a.jpg",[114,114],"https:\u002F\u002Flh3.googleusercontent.com\u002FjAvDGuo8o3mt8qow1oD3zHYQ49qId7Oac0kF7rVXD9XwI-68SffddoinMXIGomoJqHc8MDDb0U2gazqmtJR6tjVfj6kS2DSR",[116],{"id":21,"title":22},"Keiron Printing Technologies, pionier op het gebied van Laser-Induced Forward Transfer (LiFT) voor uiterst nauwkeurig soldeerpastaprinten, maakt vandaag bekend "]